Sentien Biotech
↗Lexington, Massachusetts, United States
Sentien Biotechnologies is a privately-held, clinical-stage company developing novel ex vivo cell therapies designed to restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach utilizes mesenchymal stromal cells (MSCs) immobilized within an extracorporeal device to enable sustained, controlled delivery of anti-inflammatory and regenerative factors. The company's flagship product, SBI-101, represents a novel combination device-drug therapy approach that enables dynamic dosing of MSC-secreted factors without direct cell injection, addressing critical unmet needs in acute organ failure and sepsis-related complications.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:Regenerative Medicine/Cell Therapy
SIZE & FINANCIALS
Employees:1-50
Founded:2008
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$13M
Investors:Boehringer Ingelheim Venture Fund USA, BioInnovation Capital, Chiesi Ventures, MBL Venture Capital, Mass Medical Angels, Mission BioCapital, Pappas Capital
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Cell therapy, Mesenchymal Stromal Cells (MSCs), Ex vivo delivery device, Combination device-drug
Active Trials:2
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:BARDA (Biomedical Advanced Research and Development Authority), U.S. Department of Defense and Medical Technology Enterprise Consortium, Maryland Stem Cell Research Fund (MSCRF)
COMPETITION
Position:Niche Player
Competitors:Nimbus Therapeutics, Escient Pharmaceuticals, Alpine Immune Sciences, Atox Bio, AM-Pharma Holding, Quark Pharmaceuticals, LG Chem, Pharming Group +5 more
LEADERSHIP
Key Executives:
Brian Miller - CEO & Co-Founder
Biju Parekkadan - Scientific Co-Founder & Director
Allen Nissenson - Chief Medical Officer
Rita Barcia - Vice President, Research and Development
Scientific Founders:Biju Parekkadan, PhD
Board Members:Brian Miller (CEO & Director), Richard Ganz (Chairman), Johannes Fruehauf (Board Member/Advisor)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sentien Biotech. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.